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They are effective in the treatment of candidaemia, esophaegeal
candidaisis, and aspergillus infections. Selected agents can also
be used for prophylaxis in stem cell transplant recipients and
other candida infections. Currently, there are 3 echinocandins
available, caspofungin, micafungin and anidulafungin. No dosage
adjustment is required for renal impairment. Only caspofun-
gin requires adjustment in liver insufﬁciency. Pharmacokinetic-
pharmacodynamic studies have identiﬁed that these agents are
concentration dependent with post-antifungal effect. Therefore
a single daily dosing regimen is usually sufﬁcient. In addition,
novel dosing regimen such as extended interval dosing (alternate
day or even weekly) may be possible as demonstrated in animal
models. While these agents have demonstrated similar efﬁcacy,
patients’ comfort would be another considerations in the choice
of anti-infective agents. Possibility on extended interval dosing,
and drug cost would impact on the hospital decision on their
formulary placement.
Concurrent Session 4 – HCV Development and
Strategies
CS4-01 Response-guided Therapy for Chronic Hepatitis C
Stefan Zeuzem*. Professor of Medicine, Chief, Department of
Medicine, Goethe University Hospital, Frankfurt a.M., Germany
Pegylated interferon alfa in combination with ribavirin admin-
istered for 48 and 24 weeks has been approved as standard
antiviral treatment in patients with HCV genotype 1 (4-6) and
2/3 infection, respectively, in many countries. Different virus-
and host-related baseline parameters are known to predict
the probability of sustained virologic response including HCV
genotype, HCV viral load, gamma glutamyltranspeptidase (GGT)
levels, age and liver ﬁbrosis. While HCV genotype 2, 3 infected
patients are generally treated for 24 weeks, management of
therapy is based on early discontinuation rules in HCV genotype
1 infected patients with a low or no chance of further sustained
virologic response. Thereby, a decline of less than 2 log10 steps
at week 12 in comparison with baseline (early virologic response,
EVR) and detectable HCV RNA at week 24 by a sensitive assay
(detection limit ≤50 IU/ml) can be safely used as stopping rules
with predictive values of 98-100% for virologic non-response. Fu-
ture developments are aiming for individualization of treatment
duration based on HCV RNA concentrations before initiation
of therapy and decline early during therapy. Rapid virologic
response (RVR) deﬁned as undetectable HCV RNA at week 4
of therapy (≤50 IU/ml) together with low baseline viral load
(≤600.000 IU/ml) were introduced as parameters for shortening
of treatment duration in HCV genotype 1 infected patients with-
out a loss of the probability of sustained virologic response. Vice
versa in patients with a slow virologic response which become
HCV RNA negative at the ﬁrst time at week 24 of therapy prolon-
gation of treatment duration to 72 weeks seems to be associated
with increased sustained virologic response rates. Similar in HCV
genotype 2, 3 infected patients reduction of treatment duration
from 24 to 12-16 weeks was investigated in different clinical
trials. However, in several studies shortening therapy to 12-16
weeks higher relapse rates were reported and future trials are
needed to deﬁne subgroups of patients with speciﬁc baseline
parameters (e.g. genotype, viral load, degree of ﬁbrosis) and
RVR at week 4 for a safe reduction of treatment duration.
Basic to the development of new speciﬁc anti-HCV drugs is the
understanding of the viral life cycle, in particular the genomic or-
ganization and the polyprotein processing. Major progress in this
ﬁeld was achieved due to the development of sub-genomic and
more recently full-genomic replicon systems. The HCV genome
is a single-stranded RNA molecule that contains a single open
reading frame encoding a polyprotein of about 3000 amino acids.
The polyprotein is subsequently processed at the level of the
endoplasmic reticulum (ER) by cellular and viral proteases to
yield 4 structural and 6 non-structural proteins. The open read-
ing frame is ﬂanked by 5’ and 3’ untranslated regions. Each
single HCV structure represents a potential antiviral target. An-
tisense oligonucleotides, ribozymes, siRNA, and small molecules
have been targeted in particular against the 5’-noncoding region
with substantial success in vitro but not yet in vivo. Inhibition
of nucleocapsid formation to the icosahedral viral coat is an
attractive target, however, no speciﬁc molecules have yet been
developed. Envelope proteins HCV E1 and E2 are the basis for the
development of prophylactic and/or therapeutic vaccines.
NS3 and NS4A are cleaved by the catalytic activity of the NS3
protease domain. In addition to the protease domain located in
the 189 aminoterminal amino acids, NS3 also possesses a helicase
domain located in the 442 carboxyterminal amino acids. The
NS3 protease domain is responsible to complete the polyprotein
processing down to NS4B, NS5A, and NS5B. Despite the fact that
the catalytic site is a shallow and largely hydrophobic groove and
therefore very difﬁcult to target several compounds have been
successfully designed (BILN 2061, VX-950, SCH503034, etc.). The
NS5B RNA-dependent RNA polymerase is the key enzyme for syn-
thesis of a complementary minus-strand RNA using the genome as
template, and the subsequent synthesis of genomic plus-strand
RNA from this minus-strand RNA template. The active site of
the enzyme is a target for nucleoside/nucleotide analogue in-
hibitors. Nonnucleoside inhibitors, reported to bind at various
sites, may act by blocking the enzyme in the initiation mode
through inhibition of a conformational change needed to proceed
with elongation.
CS4-02 Treatment of Different Genotypes in Chronic
Hepatitis C
James Y.Y. Fung*. Department of Medicine, University of Hong
Kong, Hong Kong
Hepatitis C virus (HCV) affects an estimated 175 million people
worldwide. Up to 4 million people will be newly infected each
year, and the majority of these will progress to chronic infec-
tion. There are currently six major genotypes, with geographical
differences in the distribution of these different genotypes. In
China, the predominant genotypes are 1b and 2a, compared to
Hong Kong, where the predominant genotypes are 1b and 6.
The most important clinical implication of HCV genotypes lies
in the differences in response to antiviral therapy between the
different genotypes, and HCV genotypes is the strongest pre-
dictor of treatment response. Therefore, the determination of
HCV genotype has become an essential part in the treatment of
chronic hepatitis C. The exact mechanism of why some geno-
types are more difﬁcult to treat than others remains unknown,
and is likely to involve both host and viral factors. With our
current knowledge, patients infected with genotype 1 and 4 have
an inferior response to interferon-based therapy compared to
patients with genotypes 2, 3, 5 and 6.
CS4-03 Mechanism of IFN-gamma in Anti-HCV Infection
Xuefan Bai *. Department of Infectious Diseases, Tangdu
Hospital, Fourth Military Medical University, Xi’an, China
CS4-04 The Impact of Lipid Proﬁles on HCV RNA Levels in
Patients with Genotypes 1 and 2
Chen-Hua Liu*. Department of Internal Medicine, National
Taiwan University Hospital, Taipei, Taiwan
Chronic hepatitis C virus (HCV) infection, a leading cause of cir-
rhosis, hepatocellular carcinoma (HCC) and liver failure, affects
more than 170 million people worldwide. Despite the improving
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sustained virologic response (SVR) rates with the currently ap-
proved interferon-based therapies, these therapies are limited
by the on-treatment side effects and by the relatively inferior
response in patients with HCV genotype 1 infection. Several host
and viral factors have been implicated to inﬂuence the disease
progression and the treatment response in chronic hepatitis
C (CHC) patients, and efforts to modify these factors to the
optimize the therapeutic response are ungently needed.
Recently, host metabolic factors, such as diabetes mellitus (DM),
insulin resistance (IR), hepatic steatosis, and impaired lipid
metabolism have been found to closely associated with HCV
infection. Ample clinical evidence indicate that deranged lipid
proﬁles and hepatic steatosis correlate with HCV infection, sug-
gesting their potential roles of predicting therapeutic responses.
Furthermore, it has been demonstrated in vitro that the lipid
rafts, mainly composed of cholesterol and sphingolipid, and the
lipid droplet, an organelle for storing neutral lipids, play the cru-
tial roles of producing infectious viruses. While HCV genotypes 3
virus may directly cause hepati steatosis, the association of viral
loads in HCV genotype 1 or 2 virues, the mainly types in infected
individuals in the world, with the lipid proﬁles still remains
elusive. The search of the association between lipid proﬁles and
the HCV genotypic differences is therefore important.
A recent study recruting 531 patients with either HCV genotype
1 or 2 infection showed that high serum triglyceride, totoal
cholesterol and low-density lipoprotein (LDL) correlated with
high HCV RNA levels. In patients with low body mass index (BMI),
high modeal assessment of insulin resistance index (HOMA-IR)
and total cholesterol levels were associated with high HCV viral
load. After stratiﬁcation by HCV genotypes, lipid proﬁles were
highly associated with HCV viral load in genotype 2, rather than
genotype 1 patients. The study indicated that differed mecha-
nisms of deranged lipid proﬁles between HCV genotype 1 and
2 viruses. Because the casual relationship of the viral load and
the lipid proﬁles are still to be determined, manipulation of the
lipid proﬁles aiming in improving the anti-HCV therapy deserves
further studies.
Concurrent Session 5 – Gram-Negative Bacterial
Infections and Resistance
CS5-01 Complete Genome Sequence and Proteome of
Laribacter hongkongensis, a Novel Bacterium
Associated with Gastroenteritis and Traveler’s
Diarrhea
Patrick C.Y. Woo*. Department of Microbiology, The University
of Hong Kong, Hong Kong, China
Despite extensive investigations, a microbiological cause cannot
be found in about half of the patients with infectious disease.
Throughout the years, scientists have spent tremendous efforts
in looking for microorganisms associated with these “unexplained
infectious disease syndromes”. In 2001, we discovered Laribac-
ter hongkongensis gen. nov. sp. nov., a facultative anaerobic,
Gram-negative, S-shaped, urease-positive rod of the Neisseri-
aceae family, from blood and empyema thoracis of a patient with
alcoholic cirrhosis. During the past eight years, we have docu-
mented that L. hongkongensis was associated with community
acquired gastroenteritis and traveler’s diarrhea and cases were
found globally in patients who resided in or had recent travel
histories to countries in Asia, Europe, America and Africa. We
have found that freshwater ﬁsh is the reservoir and it was also
found in Chinese tiger frogs and drinking water reservoirs. Due
to the potential of its clinical importance and related ecology,
important phenotypic characteristics and phylogenetic position,
and the availability of genetic manipulation systems for down-
stream experiments, we sequenced the complete genome of L.
hongkongensis, with the aim of achieving better understanding
of its biology, mechanism of adaptation to different hosts, and
virulence mechanisms. The complete genome sequence of L.
hongkongensis consists of a 3,169-kb chromosome with G+C con-
tent of 62.35%. Genome analysis reveals different mechanisms
potentially important for its adaptation to diverse habitats of hu-
man and freshwater ﬁsh intestines and freshwater environments.
The gene contents suggest that amino acids and fatty acids can
be used as carbon sources. The extensive variety of transporters
including multidrug efﬂux and heavy metal transporters, as well
as genes involved in chemotaxis may enable L. hongkongensis
to survive in different environmental niches. Genes encoding
urease, bile salts efﬂux pump, adhesin, catalase, superoxide dis-
mutase and other putative virulence factors, such as hemolysins,
RTX toxins, patatin-like proteins, phospholipase A1 and colla-
genases, are present. Proteomes of L. hongkongensis cultured
at 37°C and 20°C showed differential gene expression, includ-
ing two homologous copies of argB, argB-20 and argB-37, that
encode two isoenzymes of N-acetyl-L-glutamate kinase (NAGK),
NAGK-20 and NAGK-37, in the arginine biosynthesis pathway.
NAGK-20 showed higher expression at 20°C whereas NAGK-37
showed higher expression at 37°C. NAGK-20 also had a lower
optimal temperature for enzymatic activities and was inhibited
by arginine probably as negative feedback control. Similar du-
plicated copies of argB are also observed in bacteria from hot
springs, including Thermus thermophilus, Deinococcus geother-
malis, Deinococcus radiodurans and Roseiﬂexus castenholzii,
suggesting that similar mechanisms for temperature adaptation
may be employed by other bacteria.
CS5-02 Resistance Trends and Treatment Options of
Infections of Gram-negatives
Minggui Wang*. Huashan Hospital, Fudan University, Shanghai,
China
Increasing antimicrobial resistance brings difﬁculties for selec-
tion of effective antimicrobial regimens in the treatment of
bacterial infections. Antimicrobial resistance trends and ther-
apeutic options will be discussed for the following highly an-
timicrobial resistant gram-negative bacilli: ESBL-producing Es-
cherichia coli and Klebsiella pneumoniae, and multiple-resistant
Pseudomonas aeruginosa and Acinetobacter baumannii. ESBLs-
producing strains of E. coli and K. pneumoniae have been
increasing and currently approximately half of the strains pro-
duce ESBLs in China. Carbapenems produce the best outcomes
in the treatment of ESBLs infections. In vitro ESBL-producing
organisms vary in their susceptibility to other antimicrobials.
The susceptibility rates of ESBL-producing strains are relatively
high to β-lactamase inhibitor combinations such as cefoperazone-
sulbactam and piperacillin-tazobactam, which might be used in
the treatment of such infections in high dosage. The isolation
of P. aeruginosa and A. baumannii, the most common pathogens
in ventilator-associated pneumoniae (VAP), has been increas-
ing in clinical specimens. Both P. aeruginosa and A. baumannii
are non-fermenters, which are highly resistant to antimicrobial
agents. According to a bacterial surveillance program, CHINET,
in China, the resistance rates of P. aeruginosa clinical strains
to ceftazidime, piperacillin-tazobactam, imipenem, meropenem
and ciproﬂoxacin were from 21% to 30% in 2008, while the
resistance rates were relatively lower to amikacin, cefepime
and cefoperazone-sulbactam with resistance rates from 15% to
18%. Acinetobacter spp. was more resistant to most antimicro-
bials than did P. aeruginosa. The choice of antimicrobial agents
should be based on the in-vitro susceptibility results. For severe
infections, combination therapy is recommended as following:
an active β-lactam combined with an aminoglycoside or with a
quinolone such as ciproﬂoxacin or levoﬂoxacin. A. baumannii is
highly susceptible to doxycycline or minocycline, but the clinical
experience is limited. Colistin has emerged again as a thera-
peutic option for pandrug resistant (PDR) P. aeruginosa and A.
